Opinion: STAT+: Reimagining R&D can cut drug development costs from billions to millions

Biopharma companies need to move away from siloed, incremental change and embrace full-scale transformation of their R&D pipelines and operations.

In the course of our work advising biopharma companies, we are often asked how they can bring medicines to market more quickly and cost efficiently. It’s a timely question.

It can take 10 to 15 years and cost between $2.6 billion and $6.7 billion — including the cost of capital and the cost of failure — to bring a successful medicine to market, depending on therapeutic area, treatment modality, and disease complexity. While the biopharma industry continues to innovate — look no further than its speedy response to Covid-19 — those costs and timelines are no longer sustainable.

Continue to STAT+ to read the full story…